4-苄氨基-7-硝基苯并-2-氧杂-1,3-二唑 | 18378-20-6

• 物质功能分类: 生物化工 - 生化试剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 中文名称: 4-苄氨基-7-硝基苯并-2-氧杂-1,3-二唑
• 中文别名: 4-苄基氨基-7-硝基苯并氧杂恶二唑(BBD)；4-苄基氨基-7-硝基苯并氧杂恶二唑；4-苄基氨基-7-硝基苯并-2-氧杂-1,3-二唑；BBD
• 英文名称: N-benzyl-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine
• 英文别名: 7-(benzylamino)-4-nitrobenz-2-oxa-1,3-diazole；Bn-NBD；benzyl-(7-nitro-benzo[1,2,5]oxadiazol-4-yl)-amine；7-nitro-N-(benzyl)benzofurazan-4-amine；4-benzylamino-7-nitrobenzofurazan；7-Benzylamino-4-nitrobenz-2-oxa-1,3-diazol；7-Benzylamino-4-nitrobenz-2-oxa-1,3-diazole；N-benzyl-4-nitro-2,1,3-benzoxadiazol-7-amine
• CAS: 18378-20-6
• 化学式: C₁₃H₁₀N₄O₃
• mdl: MFCD00038006
• 分子量: 270.247
• InChiKey: GZFKJMWBKTUNJS-UHFFFAOYSA-N

物化性质

• 熔点：
  206-209 °C
• 沸点：
  413.36°C (rough estimate)
• 密度：
  1.2858 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  96.8
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2921499090
• 安全说明：
  S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	Bbd Material Safety Data Sheet
Synonym:	4-Benzylamino-7-nitrobenzofurazan; 7-Benzylamino-4-nitrobenz-2-oxa-1,3-diazole
CAS:	18378-20-6

Section 1 - Chemical Product MSDS Name:Bbd Material Safety Data Sheet
Synonym:4-Benzylamino-7-nitrobenzofurazan; 7-Benzylamino-4-nitrobenz-2-oxa-1,3-diazole

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
18378-20-6	Bbd	ca.100	242-261-5

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed.
Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 18378-20-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use. Wear a NIOSH/MSHA or European Standard EN 149 approved full-facepiece airline respirator in the positive pressure mode with emergency escape provisions.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: brown
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 206.00 - 209.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H10N4O3
Molecular Weight: 270.25

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 18378-20-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Bbd - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 18378-20-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 18378-20-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 18378-20-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性方面，Benzylamino-NBD（BBD, NSC240867）是一种生化显色剂。其主要用途为蛋白质荧光探针。

反应信息

• 作为产物：
  描述：

  2,6-二氯亚硝基苯 在 硫酸 、 硝酸 作用下， 以 乙醇 为溶剂， 生成 4-苄氨基-7-硝基苯并-2-氧杂-1,3-二唑
  参考文献：
  名称：

  潜在的抗白血病和免疫抑制药物。一些苯并-2,1,3-恶二唑（苯并呋喃）及其N-氧化物（苯并呋喃）的制备及其体外药理活性。

  摘要：

  DOI：

  10.1021/jm00308a027

文献信息

• [EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET UTILISATIONS ASSOCIÉES
  申请人：CELGENE AVILOMICS RES INC

  公开号：WO2014144737A1

  公开（公告）日：2014-09-18

  The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.

  本发明涉及作为蛋白激酶抑制剂的化合物，这些化合物在ATP结合位点包含一个半胱氨酸残基。该发明还提供了包含一种或多种蛋白激酶抑制剂化合物的药用可接受组合物，以及使用所述组合物治疗癌症和癌的方法。
• [EN] MK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS MK2 ET UTILISATIONS ASSOCIÉES
  申请人：CELGENE AVILOMICS RES INC

  公开号：WO2014149164A1

  公开（公告）日：2014-09-25

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• Pharmacophore identification of c-Myc inhibitor 10074-G5
  作者：Jeremy L. Yap、Huabo Wang、Angela Hu、Jay Chauhan、Kwan-Young Jung、Robert B. Gharavi、Edward V. Prochownik、Steven Fletcher

  DOI：10.1016/j.bmcl.2012.10.013

  日期：2013.1

  relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1′-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) – which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues – was executed in order to determine its pharmacophore. Whilst the 7-nitrobenzofurazan was found to be critical for inhibitory activity, the ortho-biphenyl could be replaced with

  c-Myc (Myc) 抑制剂 10074-G5 ( N -([1,1'-biphenyl]-2-yl)-7-nitrobenzo[ c ][1,2, 5]oxadiazol-4-amine, 1 ) – 其目标是侧翼为精氨酸残基的 Myc 癌蛋白的疏水结构域 – 被执行以确定其药效团。虽然发现 7-硝基苯并呋喃对抑制活性至关重要，但邻联苯可以被对羧基苯基取代以提供新的抑制剂 JY-3-094 ( 3q )。大约是 IC 50铅的效力的五倍33 μM 用于破坏 Myc-Max 异源二聚体，JY-3-094 表现出优于 Max-Max 同源二聚体的选择性，在 100 μM 时没有明显影响。重要的是，JY-3-094 的羧酸改善了先导化合物的理化性质，这将有助于引入额外的疏水性，从而进一步增强 Myc 抑制活性。
• [EN] METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR L'IDENTIFICATION D'INHIBITEURS DE GLYCOSYLTRANSFÉRASE
  申请人：HARVARD COLLEGE

  公开号：WO2013151697A1

  公开（公告）日：2013-10-10

  The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I).

  本发明提供了用于筛选细菌糖基转移酶抑制剂的以莫诺霉素为基础的探针化合物的公式(I)。本发明还提供了使用公式(I)化合物进行细菌糖基转移酶筛选的检测方法。
• LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN
  申请人：Petter Russell C.

  公开号：US20110269244A1

  公开（公告）日：2011-11-03

  The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.

  本发明涉及酶抑制剂。更具体地说，本发明涉及配体导向的蛋白共价修饰；相同设计方法；相同的药物配方；以及使用方法。